Pentraxin level is the key to determine primary Percutaneous Coronary Intervention (PCI) or fibrinolysis.

Pentraxin level is the key to determine primary Percutaneous Coronary Intervention (PCI) or fibrinolysis. Cardiovasc Hematol Disord Drug Targets. 2018 Nov 20;: Authors: Haybar H, Parsa SA, Khaheshi I, Zayeri ZD Abstract AIM: To examine if pentraxin can help identifying patients benefitting most from primary Percutaneous Coronary Intervention (PCI) vs. fibrinolysis. METHODS: Patients with acute ST-Elevation Myocardial Infarction (STEMI) were consecutively recruited from a community center without PCI and a tertiary center with PCI facilities.Left ventricular ejection fraction (LVEF) was determined echocardiographically at baseline and 5 day after the index admission; the difference between two measurements was considered as the magnitude of improvement. We used regression models to test the hypothesis that the magnitude of the advantage of PCI over fibrinolysis in preserving LVEF 5 days after STEMI is modified by pentraxin 3 (PTX3). RESULTS: The functional advantage (LVEF) of the PCI over fibrinolysis has been determined by PTX3. LVEF attenuated and even reversed as PTX3 level increased. The primary PCI of the participants with less than 7 PTX3 level, achieved a clinically significantly increase in the LVEF in compare to fibrinolysis. At lower levels of PTX3, PCI shows a conspicuous advantage over fibrinolysis in terms of the probability of developing a LVEF
Source: Cardiovascular and Hematological Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Related Links:

Authors: Boinska J, Koziński M, Kasprzak M, Ziołkowska K, Dziembowska I, Ziołkowski M, Kubica J, Rość D Abstract The aim of the study was to evaluate diurnal changes of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) concentrations in relation to on-treatment platelet reactivity. The study group included 51 patients with acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention and dual antiplatelet therapy. TF and TFPI concentrations were assessed using enzyme-linked immunosorbent assay kits. We found a significant increase of TF concentration in clopidogrel-resis...
Source: Platelets - Category: Hematology Tags: Platelets Source Type: research
AbstractThere is still a debate about the safety and efficacy of an aspirin free strategy after percutaneous coronary intervention (PCI). Hence, we performed a meta-analysis comparing aspirin free strategy to dual antiplatlets therapy (DAPT). Randomized trials (RCTs) comparing aspirin free strategy to DAPT in patients who received PCI were included. The primary outcome of interest was bleeding, defined per the Bleeding Academic Research Consortium (BARC). Secondary outcomes included major adverse cardiovascular and cerebrovascular events (MACE); defined as all-cause mortality, myocardial infarction or stroke, the individua...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
This study sought to examine the in-hospital mortality, temporal trends and resource utilization in early vs. delayed IHCA in STEMI.
Source: Resuscitation - Category: Emergency Medicine Authors: Tags: Clinical paper Source Type: research
While primary percutaneous coronary intervention (PPCI) in ST-elevation myocardial infarction (STEMI) restores normal epicardial flow, limitations remain, including persistently impaired myocardial perfusion which in part is due to thrombotic embolization.1 This has been associated with worsened myocardial salvage2 and increased mortality.3 –5 Roughly one-quarter of patients will have impaired microvascular flow following reperfusion in STEMI.2 Moreover, distal embolization of intracoronary (IC) thrombus during mechanical intervention can lead to further infarct expansion.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Authors: Kim BS, Eom SY, Kim SH, Hwang HK, Park JS, Kim W, Lee JW, Rha SW, Kim GY, Lim SW, Lee SH, Chae JK, Woo SI, Bae JW, Kim HJ Abstract The efficacy of pre-procedural beta-blocker use in patients with acute coronary syndrome (ACS) is not well established in the current percutaneous coronary intervention (PCI) era. We investigate the effect of pre-procedural beta-blocker use on clinical outcomes in patients with ACS undergoing PCI. Among 44,967 consecutive cases of PCI enrolled in the nationwide, retrospective, multicenter registry (K-PCI registry), 31,040 patients with ACS were selected and analyzed. We classif...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
We read the recent case report by Idris et al. [1] about acute myocardial infarction presenting with left bundle branch block and Chapman ’s sign with great interest. Although it is a very interesting case report, we want to address some points that need more attention.
Source: The American Journal of Emergency Medicine - Category: Emergency Medicine Authors: Source Type: research
For patients suffering from acute ST-elevation myocardial infarction (STEMI), it is controversial whether infarct location predicts worse clinical outcome independently of infarct size. We therefore aimed to investigate the prognostic relevance of infarct location in relation to infarct size in STEMI patients treated with contemporary primary percutaneous coronary intervention (PCI).
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
This study showed that efficacy of 0.9 and 1.4 mm excimer laser catheter was equivalent in ELCA for AMI patients. If o ne takes into account lesion crossability, debulking effects, and the stunned platelets phenomenon, the 0.9 mm excimer laser catheter is sufficient for ELCA in AMI patients.
Source: Lasers in Medical Science - Category: Laser Surgery Source Type: research
AbstractDiabetes mellitus (DM) is an independent predictor of adverse outcomes in patients with coronary artery disease (CAD). We investigated the interaction between DM and high platelet reactivity (HPR) in determining long-term clinical outcomes after percutaneous coronary intervention (PCI). We enrolled 500 patients who were divided based on the presence of DM and HPR. Primary endpoint was the occurrence of major adverse clinical events (MACE) at 5  years. Patients with both DM and HPR showed the highest estimates of MACE (37.9%, log-rankp 
Source: Journal of Cardiovascular Translational Research - Category: Cardiology Source Type: research
ABSTRACTBackgroundTrends and clinical factors associated with prescribing choices for oral P2Y12 inhibitors (P2Y12-I) remain unknown for patients on chronic dialysis, i.e., with end-stage renal disease (ESRD).MethodsFrom 2011 –2014 U.S. Renal Data System registry, we identified 36,542 ESRD patients who received new prescriptions for P2Y12-I (median age 64.0 years and 54% males). Of the cohort, 93% were receiving hemodialysis and 7% on peritoneal dialysis. We analyzed trends and investigated clinical factors associated with specific P2Y12-I prescribed.ResultsClopidogrel was prescribed for 95%, prasugrel for 3%, and ti...
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Angioplasty | Cardiology | Cardiovascular | Coronary Angioplasty | Drugs & Pharmacology | Heart | Heart Attack | Hematology | Percutaneous Coronary Intervention